Assessment of HB-EGF Levels in Peritoneal Fluid and Serum of Ovarian Cancer Patients Using ELISA

Overview

Journal Anticancer Res

Specialty Oncology

Date 2011 Aug 30

PMID 21873174

Citations 5

Authors

Shoko Hikita

Fusanori Yotsumoto

Tatsuya Fukami

Tatsuya Fumaki

Shinji Horiuchi

Ayako Sanui

Kohei Miyata

Sung Ouk Nam

Hiroshi Tsujioka

Taeko Ueda

Kyoko Shirota

Toshiyuki Yoshizato

Kazuhiro Maeda

Toyokazu Ishikawa

Yoshinobu Okuno

Masahide Kuroki

Eisuke Mekada

Shingo Miyamoto

Affiliations

Soon will be listed here.

Abstract

Background: Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a rational target for ovarian cancer therapy. The aim of this study was to examine HB-EGF levels in the peritoneal fluid and serum of ovarian cancer (OVCA) patients.

Patients And Methods: Samples were collected from six healthy women, 21 OVCA patients, and 21 ovarian cyst patients. HB-EGF levels were measured using a sandwich ELISA kit and calculated using a parallel line assay.

Results: No significant difference between the slopes of the standard and sample curves was observed at an anti-HB-EGF antibody concentration of 1.6 μg/ml. HB-EGF levels in the peritoneal fluid and serum of OVCA patients were significantly higher than those in patients with ovarian cysts or controls. Serum HB-EGF levels were also significantly correlated with levels in peritoneal fluid in OVCA patients.

Conclusion: We developed an assay for the exact measurement of HB-EGF levels in peritoneal fluid and serum.

Citing Articles

The Multiple Functions of HB-EGF in Female Reproduction and Related Cancer: Molecular Mechanisms and Targeting Strategies.

Zhang Y, Tang L, Liu H, Cheng Y Reprod Sci. 2024; 31(9):2588-2603.

PMID: 38424408 DOI: 10.1007/s43032-024-01454-6.

BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study.

Miyamoto S, Yotsumoto F, Ueda T, Fukami T, Sanui A, Miyata K BMC Cancer. 2017; 17(1):89.

PMID: 28143428 PMC: 5286856. DOI: 10.1186/s12885-017-3071-5.

M2 macrophages induce ovarian cancer cell proliferation via a heparin binding epidermal growth factor/matrix metalloproteinase 9 intercellular feedback loop.

Carroll M, Kapur A, Felder M, Patankar M, Kreeger P Oncotarget. 2016; 7(52):86608-86620.

PMID: 27888810 PMC: 5349939. DOI: 10.18632/oncotarget.13474.

High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation.

Bourgeois D, Kabarowski K, Porubsky V, Kreeger P Cancer Cell Int. 2015; 15:112.

PMID: 26648788 PMC: 4672525. DOI: 10.1186/s12935-015-0263-4.

Soluble heparin-binding EGF-like growth factor (HB-EGF) detected by newly developed immuno-PCR method is a clear-cut serological biomarker for ovarian cancer.

Kasai N, Kobayashi K, Shioya S, Yoshikawa Y, Yotsumoto F, Miyamoto S Am J Transl Res. 2012; 4(4):415-21.

PMID: 23145209 PMC: 3493029.